Literature DB >> 24328869

Tumoral epileptogenicity: how does it happen?

Johan Pallud1, Laurent Capelle, Gilles Huberfeld.   

Abstract

Gliomas are the most frequent primary brain tumors and most glioma patients have seizures. The origin and mechanisms of human glioma-related epilepsy are multifactorial and an intermix of oncologic and neuronal processes. In this brief review, we show that the infiltrated peritumoral neocortex appears to be the key structure for glioma-related epileptic activity, which depends on the interactions between the tumor per se and the surrounding brain. We shed light on the underlying mechanisms from two different "tumorocentric" and "epileptocentric" approaches, with a special emphasis on the glioma-related glutamatergic and γ-aminobutyric acid (GABA)ergic changes leading to epileptogenicity. Because gliomas use the neurotransmitter glutamate as a "tumor growth factor" to enhance glioma cell proliferation and invasion with neurotoxic, proinvasive, and proliferative effects, glutamate homeostasis is impaired, with elevated extracellular glutamate concentrations. Such excitatory effects contribute to the generation of epileptic activity in the peritumoral neocortex. GABAergic signaling is also involved both in tumor growth and in paradoxical excitatory effects mediated by alterations in neuronal and tumor cell Cl(-) homeostasis related to cotransporter changes. Local excitability may also be affected by an increase in extracellular K(+) concentration, the alkalization of peritumoral neocortex, and alterations of gap-junction functioning. Finally, the tumor itself may mechanically affect locally neuronal behavior, connections, and networks. Better understanding of glioma-related oncologic and epileptologic processes are crucial for development of combined therapeutic strategies, but so far, the surgical management of gliomas should comprise a maximally safe surgical resection encompassing peritumoral neocortex. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Chloride; Epilepsy; GABA; Glioma; Glutamate

Mesh:

Year:  2013        PMID: 24328869     DOI: 10.1111/epi.12440

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  28 in total

1.  High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.

Authors:  Mai Froberg Sørensen; Sólborg Berglind Heimisdóttir; Mia Dahl Sørensen; Casper Schau Mellegaard; Helle Wohlleben; Bjarne Winther Kristensen; Christoph Patrick Beier
Journal:  J Neurooncol       Date:  2018-02-05       Impact factor: 4.130

2.  Do not omit the grade of malignancy when correlating the lobar location of diffuse gliomas and the risk of preoperative epileptic seizures.

Authors:  Johan Pallud; Marc Zanello; Alexandre Roux
Journal:  Neurosurg Rev       Date:  2018-10-11       Impact factor: 3.042

Review 3.  Epileptic seizure in primary intracranial sarcoma: a case report and literature review.

Authors:  Yen-Ping Chen; Hsiu-Fen Lee; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2016-07-12       Impact factor: 1.475

4.  Brain tumors in eloquent areas: A European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis.

Authors:  Giannantonio Spena; Philippe Schucht; Kathleen Seidel; Geert-Jan Rutten; Christian Franz Freyschlag; Federico D'Agata; Emanule Costi; Francesca Zappa; Marco Fontanella; Denys Fontaine; Fabien Almairac; Michele Cavallo; Pasquale De Bonis; Gerardo Conesa; Nicholas Foroglou; Santiago Gil-Robles; Emanuel Mandonnet; Juan Martino; Thomas Picht; Catarina Viegas; Michel Wager; Johan Pallud
Journal:  Neurosurg Rev       Date:  2016-08-01       Impact factor: 3.042

5.  Activation of the mTOR signaling pathway in peritumoral tissues can cause glioma-associated seizures.

Authors:  Yang Yuan; Wang Xiang; Liu Yanhui; Liang Ruofei; Luo Jiewen; Jiang Shu; Mao Qing
Journal:  Neurol Sci       Date:  2016-09-19       Impact factor: 3.307

6.  Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis.

Authors:  Yinyan Wang; Xing Fan; Wei Zhang; Chuanbao Zhang; Jiangfei Wang; Tao Jiang; Lei Wang
Journal:  J Neurooncol       Date:  2014-12-16       Impact factor: 4.130

Review 7.  Epilepsy and brain tumors.

Authors:  Dario J Englot; Edward F Chang; Charles J Vecht
Journal:  Handb Clin Neurol       Date:  2016

Review 8.  Seizure prognosis in brain tumors: new insights and evidence-based management.

Authors:  Charles J Vecht; Melissa Kerkhof; Alberto Duran-Pena
Journal:  Oncologist       Date:  2014-06-04

Review 9.  Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.

Authors:  Terri S Armstrong; Robin Grant; Mark R Gilbert; Jong Woo Lee; Andrew D Norden
Journal:  Neuro Oncol       Date:  2015-11-02       Impact factor: 12.300

10.  Compromised GABAergic inhibition contributes to tumor-associated epilepsy.

Authors:  Georgina MacKenzie; Kate K O'Toole; Stephen J Moss; Jamie Maguire
Journal:  Epilepsy Res       Date:  2016-07-27       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.